RHYTHM Biosciences Ltd
Rhythm Biosciences Limited, a medical diagnostics company, provides blood tests for the detection of cancers in Australia and the United States. It offers ColoSTAT, a blood test for the early detection of colorectal cancer; and geneType, a personalized predictive test for predicting risk of chronic disease development. The company was incorporated in 2017 and is headquartered in Parkville, Austra… Read more
Market Cap & Net Worth: RHYTHM Biosciences Ltd (RHY)
RHYTHM Biosciences Ltd (AU:RHY) has a market capitalization of $43.66 Million (AU$70.52 Million) as of March 18, 2026. Listed on the AU stock exchange, this Australia-based company holds position #23390 globally and #464 in its home market, demonstrating a 16.22% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying RHYTHM Biosciences Ltd's stock price AU$0.22 by its total outstanding shares 327979001 (327.98 Million).
RHYTHM Biosciences Ltd Market Cap History: 2017 to 2026
RHYTHM Biosciences Ltd's market capitalization history from 2017 to 2026. Data shows change from $56.86 Million to $43.66 Million (-4.87% CAGR).
RHYTHM Biosciences Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how RHYTHM Biosciences Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
8.59x
RHYTHM Biosciences Ltd's market cap is 8.59 times its annual revenue
0.68x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $28.43 Million | $64.48K | -$1.75 Million | 440.93x | N/A |
| 2019 | $26.40 Million | $1.03 Million | -$2.55 Million | 25.68x | N/A |
| 2020 | $177.70 Million | $100.00K | -$4.02 Million | 1776.95x | N/A |
| 2021 | $314.77 Million | $1.11 Million | -$6.61 Million | 283.84x | N/A |
| 2022 | $201.05 Million | $2.43 Million | -$8.79 Million | 82.84x | N/A |
| 2023 | $27.42 Million | $3.10 Million | -$8.22 Million | 8.86x | N/A |
| 2024 | $17.67 Million | $1.69 Million | -$6.86 Million | 10.45x | N/A |
| 2025 | $27.42 Million | $3.19 Million | -$3.83 Million | 8.59x | N/A |
Competitor Companies of RHY by Market Capitalization
Companies near RHYTHM Biosciences Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to RHYTHM Biosciences Ltd by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #91 globally with a market cap of $176.18 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #154 globally with a market cap of $120.38 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #466 globally with a market cap of $46.34 Billion USD.
- Lonza Group Ltd (PINK:LZAGF): Ranked #512 globally with a market cap of $41.73 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #91 | Thermo Fisher Scientific Inc | NYSE:TMO | $176.18 Billion | $470.00 |
| #154 | Danaher Corporation | NYSE:DHR | $120.38 Billion | $191.39 |
| #466 | IDEXX Laboratories Inc | NASDAQ:IDXX | $46.34 Billion | $586.37 |
| #512 | Lonza Group Ltd | PINK:LZAGF | $41.73 Billion | $596.13 |
RHYTHM Biosciences Ltd Historical Marketcap From 2017 to 2026
Between 2017 and today, RHYTHM Biosciences Ltd's market cap moved from $56.86 Million to $ 43.66 Million, with a yearly change of -4.87%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$43.66 Million | +59.26% |
| 2025 | AU$27.42 Million | +55.17% |
| 2024 | AU$17.67 Million | -35.56% |
| 2023 | AU$27.42 Million | -86.36% |
| 2022 | AU$201.05 Million | -36.13% |
| 2021 | AU$314.77 Million | +77.14% |
| 2020 | AU$177.70 Million | +573.08% |
| 2019 | AU$26.40 Million | -7.14% |
| 2018 | AU$28.43 Million | -50.00% |
| 2017 | AU$56.86 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of RHYTHM Biosciences Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $43.66 Million USD |
| MoneyControl | $43.66 Million USD |
| MarketWatch | $43.66 Million USD |
| marketcap.company | $43.66 Million USD |
| Reuters | $43.66 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.